CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
6 reports, 3 independent
Updated Sep 20
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.Sub-event
CRISPR Therapeutics and Vertex Pharmaceuticals announced a strategic partnership.1 source
FDA approved the gene-editing drug resulting from the partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.1 source
Casgevy receives US and European approval, marking the successful culmination of the partnership between CRISPR Therapeutics and Vertex.1 source
Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
-
Vertex Pharmaceuticals
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireCRISPR Therapeutics to Participate in Upcoming Investor Conferences ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company foc
- Motley Fool1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) CRISPR Therapeutics is the first company to secure an FDA approval of a gene-editing drug. That drug's underlying science, however
- ZacksCan CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? CRISPR Therapeutics CRSP is the first and only company in the world to market a CRISPR/Cas9-based therapy. The company tasted major su
- ZacksCRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of its in-vi
- Unknown outlet